Karst Matthias, Kegel Tanja, Lukas Anne, Lüdemann Wolf, Hussein Samii, Piepenbrock Siegfried
Department of Anesthesiology, Hannover Medical School, Hannover, Germany.
Neurosurgery. 2003 Aug;53(2):331-6; discussion 336-7. doi: 10.1227/01.neu.0000073530.81765.6b.
This study was designed to assess the efficacy of perioperative administration of celecoxib (Celebrex; Pharmacia GmbH, Erlangen, Germany) in reducing pain and opioid requirements after single-level lumbar microdiscectomy.
We studied 34 patients (mean age, 44.26 yr; standard deviation [SD], 13.09 yr) allocated randomly to receive celecoxib 200 mg twice a day for 72 hours starting on the evening before surgery or placebo capsules in a double-blind study. Fourteen patients received 20 to 80 mg dexamethasone intravenously during surgery (mean, 40 mg; SD, 19.22 mg) because of visible signs of compression of the affected nerve root. After lumbar disc surgery, patients were monitored for visual analog scores for pain at rest and on movement, patient-controlled analgesia (PCA) piritramide requirements, and von Frey thresholds in the wound area.
Pain scores decreased and wound von Frey thresholds increased continuously until discharge, with no intergroup differences. Mean 24-hour PCA piritramide requirements were 22.63 mg (SD, 23.72 mg) and 26.14 mg (SD, 22.57 mg) in the celecoxib and placebo groups, respectively (P = not significant). However, patients with intraoperative dexamethasone (n = 14) required only 10.29 mg (SD, 8.55 mg) 24-hour PCA piritramide, in contrast to the 34.25 mg (SD, 24.69 mg) needed in those who did not receive intraoperative dexamethasone (P = 0.001). In addition, 24 hours after the operation, pain scores on movement were significantly lower in the dexamethasone subgroup (P = 0.003).
Celecoxib has no effect on postoperative pain scores and PCA piritramide requirements. The intraoperative use of 20 to 80 mg dexamethasone is able to significantly decrease postoperative piritramide consumption and pain scores on the first day after surgery.
本研究旨在评估围手术期给予塞来昔布(西乐葆;法玛西亚股份公司,德国埃尔朗根)对单节段腰椎间盘显微切除术术后疼痛及阿片类药物需求量的影响。
我们对34例患者(平均年龄44.26岁;标准差[SD]13.09岁)进行了一项双盲研究,随机分配患者在手术前一晚开始每天两次服用200毫克塞来昔布,持续72小时,或服用安慰剂胶囊。14例患者因受影响神经根有明显受压迹象,在手术期间静脉注射20至80毫克地塞米松(平均40毫克;SD19.22毫克)。腰椎间盘手术后,监测患者静息和活动时的视觉模拟疼痛评分、患者自控镇痛(PCA)哌替啶需求量以及伤口区域的von Frey阈值。
直至出院,疼痛评分降低,伤口von Frey阈值持续升高,两组间无差异。塞来昔布组和安慰剂组的平均24小时PCA哌替啶需求量分别为22.63毫克(SD23.72毫克)和26.14毫克(SD22.57毫克)(P=无显著性差异)。然而,术中使用地塞米松的患者(n=14)24小时PCA哌替啶需求量仅为10.29毫克(SD8.55毫克),而未接受术中地塞米松的患者需求量为34.25毫克(SD24.69毫克)(P=0.001)。此外,术后24小时,地塞米松亚组患者的活动时疼痛评分显著更低(P=0.003)。
塞来昔布对术后疼痛评分和PCA哌替啶需求量无影响。术中使用20至80毫克地塞米松能够显著减少术后哌替啶用量及术后第一天的疼痛评分。